Sequential release of epigallocatechin gallate and paclitaxel from PLGA-casein core/shell nanoparticles sensitizes drug-resistant breast cancer cells

Narayanan, Sreeja; Mony, Ullas; Vijaykumar, Dehannathparambil Kottarathil; Koyakutty, Manzoor; Paul‐Prasanth, Bindhu; Menon, Deepthy

doi:10.1016/j.nano.2015.03.015

Cited by 86 publications

(36 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, how to improve the solubility of PAC has become an important challenge. Currently, some methods are available for improving PAC solubility, such as the use of micelles, liposomes, and nanoparticles [7–9]. With the development of nanotechnology, the application of mesoporous materials for improving the solubility of poorly water-soluble drugs is attracting wide attention.…”

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Effect of Paclitaxel-Mesoporous Silica Nanoparticles with a Core-Shell Structure on the Human Lung Cancer Cell Line A549

Wang

Liu

2017

Nanoscale Res Lett

View full text Add to dashboard Cite

A nanodrug delivery system of paclitaxel-mesoporous silica nanoparticles with a core-shell structure (PAC-csMSN) was used to increase the dissolution of paclitaxel (PAC) and improve its treatment of lung cancer. PAC was loaded into the core-shell mesoporous silica nanoparticles (csMSN) by the adsorption equilibrium method and was in an amorphous state in terms of its mesoporous structure. In vitro and in vivo studies showed that csMSN increased the dissolution rate of PAC and improved its lung absorption. The area under concentration-time curve (AUC) value of PAC-csMSN used for pulmonary delivery in rabbits was 2.678-fold higher than that obtained with the PAC. After continuous administration for 3 days, a lung biopsy showed no signs of inflammation. Cell apoptosis results obtained by flow cytometry indicated that PAC-csMSN was more potent than pure PAC in promoting cell apoptosis. An absorption investigation of PAC-csMSN in A549 cells was carried out by transmission electron microscopy (TEM) and laser scanning confocal microscopy (LSCM). The obtained results indicated that the cellular uptake was time-dependent and csMSN was uptaken into the cytoplasm. All these results demonstrate that csMSN have the potential to achieve pulmonary inhalation administration of poorly water-soluble drugs for the treatment of lung cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

RETRACTED ARTICLE: Effect of Paclitaxel-Mesoporous Silica Nanoparticles with a Core-Shell Structure on the Human Lung Cancer Cell Line A549

Wang

Liu

2017

Nanoscale Res Lett

View full text Add to dashboard Cite

show abstract

“…The enhanced t 1/2 and K el values support the fact that the Nps resulted in longer circulation in vivo. 9,56 The organ distribution data showed early liver accumulation for free DOCT and it was reduced over time, which suggested hepatic metabolism of DOCT. The nanoformulated DOCT was observed to accumulate in all of the tested organs, but at a reduced level compared with that of free DOCT.…”

mentioning

confidence: 99%

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts

Sreeranganathan

Uthaman

Sarmento

et al. 2017

IJN

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR), upregulated in gastric cancer patients, is an oncogene of interest in the development of targeted cancer nanomedicines. This study demonstrates in silico modeling of monoclonal antibody cetuximab (CET MAb)-conjugated docetaxel (DOCT)-loaded poly(γ-glutamic acid) (γ-PGA) nanoparticles (Nps) and evaluates the in vitro/in vivo effects on EGFR-overexpressing gastric cancer cells (MKN-28). Nontargeted DOCT-γ-PGA Nps (NT Nps: 110±40 nm) and targeted CET MAb-DOCT-γ-PGA Nps (T Nps: 200±20 nm) were prepared using ionic gelation followed by 1-Ethyl-3-(3-dimethyl aminopropyl)carbodiimide–N-Hydoxysuccinimide (EDC–NSH) chemistry. Increased uptake correlated with enhanced cytotoxicity induced by targeted Nps to EGFR +ve MKN-28 compared with nontargeted Nps as evident from MTT and flow cytometric assays. Nanoformulated DOCT showed a superior pharmacokinetic profile to that of free DOCT in Swiss albino mice, indicating the possibility of improved therapeutic effect in the disease model. Qualitative in vivo imaging showed early and enhanced tumor targeted accumulation of CET MAb-DOCT-γ-PGA Nps in EGFR +ve MKN-28–based gastric cancer xenograft, which exhibited efficient arrest of tumor growth compared with nontargeted Nps and free DOCT. Thus, actively targeted CET MAb-DOCT-γ-PGA Nps could be developed as a substitute to conventional nonspecific chemotherapy, and hence could become a feasible strategy for cancer therapy for EGFR-overexpressing gastric tumors.

show abstract

“…For example, Epigallocatechin gallate (EGCG) and Paclitaxel (PTX) were co-formulated within a targeted core shell PLGA-casein nanoparticle to be released in sequence to allow for NF-κB downregulation and enhanced activity of PTX [174]. Certain NF-κB-inducible genes have been shown to protect MDA-MB-231 human breast cancer cells against Paclitaxel [175], and EGCG has demonstrated down-regulation of NF-κB amongst other key regulatory proteins [176].…”

Section: Optimal Design Of Delivery Systems For Combination Therapymentioning

confidence: 99%

“…Certain NF-κB-inducible genes have been shown to protect MDA-MB-231 human breast cancer cells against Paclitaxel [175], and EGCG has demonstrated down-regulation of NF-κB amongst other key regulatory proteins [176]. The nanoparticles re-sensitized PTX-resistant human breast cancer cells to PTX, afforded substantial cytotoxicity, and repressed expression of P-gp [174]. The nanoparticles also inhibited NF-κB activation and down-regulated several significant genes associated with angiogenesis, tumor metastasis and survival.…”

Section: Optimal Design Of Delivery Systems For Combination Therapymentioning

confidence: 99%

“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

Kemp

Shim

Heo

et al. 2016

Advanced Drug Delivery Reviews

440

258

View full text Add to dashboard Cite

a b s t r a c t a r t i c l e i n f oThe dynamic and versatile nature of diseases such as cancer has been a pivotal challenge for developing efficient and safe therapies. Cancer treatments using a single therapeutic agent often result in limited clinical outcomes due to tumor heterogeneity and drug resistance. Combination therapies using multiple therapeutic modalities can synergistically elevate anti-cancer activity while lowering doses of each agent, hence, reducing side effects. Co-administration of multiple therapeutic agents requires a delivery platform that can normalize pharmacokinetics and pharmacodynamics of the agents, prolong circulation, selectively accumulate, specifically bind to the target, and enable controlled release in target site. Nanomaterials, such as polymeric nanoparticles, gold nanoparticles/cages/shells, and carbon nanomaterials, have the desired properties, and they can mediate therapeutic effects different from those generated by small molecule drugs (e.g., gene therapy, photothermal therapy, photodynamic therapy, and radiotherapy). This review aims to provide an overview of developing multi-modal therapies using nanomaterials ("combo" nanomedicine) along with the rationale, up-to-date progress, further considerations, and the crucial roles of interdisciplinary approaches.

show abstract

Sequential release of epigallocatechin gallate and paclitaxel from PLGA-casein core/shell nanoparticles sensitizes drug-resistant breast cancer cells

Cited by 86 publications

References 39 publications

RETRACTED ARTICLE: Effect of Paclitaxel-Mesoporous Silica Nanoparticles with a Core-Shell Structure on the Human Lung Cancer Cell Line A549

RETRACTED ARTICLE: Effect of Paclitaxel-Mesoporous Silica Nanoparticles with a Core-Shell Structure on the Human Lung Cancer Cell Line A549

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts

“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

Contact Info

Product

Resources

About

Sequential release of epigallocatechin gallate and paclitaxel from PLGA-casein core/shell nanoparticles sensitizes drug-resistant breast cancer cells

Cited by 86 publications

References 39 publications

RETRACTED ARTICLE: Effect of Paclitaxel-Mesoporous Silica Nanoparticles with a Core-Shell Structure on the Human Lung Cancer Cell Line A549

RETRACTED ARTICLE: Effect of Paclitaxel-Mesoporous Silica Nanoparticles with a Core-Shell Structure on the Human Lung Cancer Cell Line A549

In vivo evaluation of cetuximab-conjugated poly(&gamma;-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts

“Combo” nanomedicine: Co-delivery of multi-modal therapeutics for efficient, targeted, and safe cancer therapy

Contact Info

Product

Resources

About

In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts